Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection

Angel N Desai; George R Thompson 3rd; Sonja M Neumeister; Anna M Arutyunova; Katelyn Trigg; Stuart H Cohen

doi:10.1001/jama.2022.15336

Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection

JAMA. 2022 Oct 4;328(13):1348-1350. doi: 10.1001/jama.2022.15336.

Authors

Angel N Desai¹, George R Thompson 3rd¹, Sonja M Neumeister¹, Anna M Arutyunova¹, Katelyn Trigg¹, Stuart H Cohen¹

Affiliation

¹ Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California.

No abstract available

Plain language summary

This case series describes the clinical resolution of systemic symptoms and lesions, along with any adverse events, in patients with monkeypox infection who were treated with tecovirimat on a compassionate use basis.

MeSH terms

Antiviral Agents* / therapeutic use
Benzamides* / therapeutic use
Compassionate Use Trials*
Humans
Isoindoles / therapeutic use
Mpox (monkeypox)* / drug therapy
Phthalimides* / therapeutic use

Substances

Antiviral Agents
Benzamides
Isoindoles
Phthalimides
tecovirimat